Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Date:9/4/2007

CALGARY, Sept. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus." The claims describe a method of using reovirus to prevent Ras-activated cancers from developing drug resistance to chemotherapeutic agents.

"Recent research conducted by the U.S. National Cancer Institute (NCI) and Cornell University demonstrated that administering reovirus in combination with various chemotherapeutic agents potentiates, or enhances tumour-killing, thus preventing the cancer cells from developing drug resistance," said Dr. Matt Coffey, Chief Scientific Officer. "This patent complements the combination REOLYSIN(R) and chemotherapy clinical program that we are pursuing in the U.K."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) -- ... and monetization of intellectual property, today announced that the ... ending June 30, 2014 on Monday, August 18, 2014 ... 10 a.m. ET on Monday, August 18, 2014 to ... by the company,s CEO, Anthony Hayes . ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... YORK , July 24, 2014 ... Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First ... "Immune" or "the Company"), announced a collaboration to ... pemphigoid last night at an event attended by ... interested parties. Lyfebulb is a health and wellness ...
Breaking Biology Technology:Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... QED International Associates, Inc.,administrator for the HealthShares(TM) Indexes, ... Exchange-Traded Funds, today announced,that effective at the opening ... Co. (NYSE: KV.A) will replace Bradley Pharmaceuticals, Inc.,(NYSE: ... Wound Care Index.,Bradley is being acquired by Nycomed ...
... CAMBRIDGE, Mass., Feb. 21 Biopure Corporation,(Nasdaq: BPUR ... fiscal,quarter ended January 31, 2008. For the quarter, the ... per common share, compared with a net loss,of $6.9 ... period in,2007. Class A common shares outstanding on January ...
... BioPharma Have Entered into an Agreement Under, Which Genmab Will ... ... USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February 21, ... ) announced today that they have entered into an agreement,under ...
Cached Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:7/24/2014)... Imagine a smog-free Los Angeles, where electric cars ply ... run on heat from beneath the earth, from howling ... new Stanford study finds that it is technically and ... one powered by clean, renewable energy. Published in ... sustainable, inexpensive and reliable energy supply in California that ...
(Date:7/24/2014)... researchers has developed a new nanoscale agent for imaging ... assessing the function and properties of the GI tract ... treatment of gut diseases. , Illnesses such ... inflammatory bowel disease all occur in the intestine and ... diseases such as diabetes and Parkinson,s. , Until ...
(Date:7/24/2014)... Environmental cleanup experts gathered at NJIT this week for ... by the U.S. Environmental Protection Agency (EPA) to dredge ... Passaic River. , The EPA has called the plan, ... sediments and capping sections of the riverbed, one of ... material would be dredged and disposed off-site. , "We ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... Calif. Scientists have long seen evidence of social behavior among ... the sea. Dolphins frolic together, lions live in packs, and ... the insects. And, right under our feet, it appears that ... the soil. Until recently, it was unknown how the worms ...
... Land areas that are a priority for wildlife conservation ... pollination, water purification, food production, and climate regulation, so ... benefits to populations in ways that are useful to ... , A global analysis published in the January ...
... of the most critical protein machines in living cells ... the U.S. Department of Energy,s Lawrence Berkeley National Laboratory ... The researchers have provided the most detailed look ever ... known as proteasomes to identify and degrade proteins that ...
Cached Biology News:Worm seeks worm: Caltech researchers find chemical cues driving aggregation in nematodes 2Worm seeks worm: Caltech researchers find chemical cues driving aggregation in nematodes 3New information on the waste-disposal units of living cells 2New information on the waste-disposal units of living cells 3
... Note: The kit contains all the reagents ... of NADPH-cytochrome c reductase activity in cell ... [endoplastic reticulum (ER)]. It has been tested ... as liver, kidney, brain, spleen, and heart ...
... Assay is an anchorage-independent growth assay in ... stringent assay for detecting malignant transformation of ... with carcinogens or carcinogen inhibitors) are cultured ... for 21-28 days. Following this incubation ...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
Biology Products: